SS-31 (elamipretide) is the most clinically advanced mitochondria-targeted peptide, currently in Phase 3 trials for multiple conditions. By directly stabilizing the inner mitochondrial membrane, it addresses mitochondrial dysfunction at its structural root rather than merely scavenging downstream oxidative damage.
Research Applications
Active clinical programs include:
- Barth syndrome: Phase 3 TAZPOWER trial (genetic cardiolipin deficiency)
- Heart failure: Phase 2 for HFpEF and HFrEF
- Mitochondrial myopathy: Phase 2 for primary mitochondrial diseases
- Aging: Preclinical data showing reversal of age-related mitochondrial decline
- Renal: Ischemia-reperfusion injury models
- Ophthalology: Age-related macular degeneration
Dosage Information (Research Use)
Clinical trial doses: 4-40mg subcutaneously daily or 0.25mg/kg IV infusion. Investigational — research use only.
Reconstitution & Handling
Standard BAC water reconstitution. Stable in solution.
Half-Life & Pharmacokinetics
Approximately 3-4 hours in plasma, but mitochondrial concentration persists significantly longer due to 1000-fold accumulation in the inner membrane.
Reported Observations in Literature
Clinical trial data: injection site reactions most common. Generally well-tolerated. Some reports of transient kidney function changes at higher IV doses.
Key Research References
- Szeto HH. “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” Br J Pharmacol. 2014
- Sabbah HN, et al. “Chronic therapy with elamipretide, a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure.” Circ Heart Fail. 2016